Endometrial carcinoma is the most common gynecologic malignancy in developed countries. Its most common symptom, postmenopausal bleeding, causes women to seek medical evaluation early, which leads to early diagnosis. The FIGO staging of this cancer is surgical-pathological. Most patients have stage I disease at diagnosis. The majority are cured by simple hysterectomy and bilateral salpingo-oophorectomy.

International, and even regional and local, differences of opinion exist as to the need to perform lymph node dissection and the extent of the lymphadenectomy in these patients. There is the need to improve the understanding of the risk-to-benefit ratio when extended surgery is performed on the typical population of women with endometrial carcinoma whose average age is 62 years and have comorbidities.

There is also debate about the need for, appropriate type of, cost-effectiveness, and efficacy of adjuvant therapy. Many patients are not surgical candidates due to comorbidities. There is a need to better understand the expected outcomes with nonsurgical therapy.

For this special issue we are calling for manuscripts that address these issues. We seek manuscripts (original research, reviews, evidence-based clinical opinion) which provide the best evidence to guide clinical practice.

The topics to be addressed include:

• Prevention, diagnosis, and pretherapy evaluation
• Molecular profile of endometrial carcinoma
• Nonsurgical therapy of endometrial carcinoma
• Type of hysterectomy (transabdominal, transvaginal, LAVH)
• Assessing the need for and extent of lymph node dissection
• Adjuvant therapies for endometrial carcinoma (to include molecular targeted therapy)

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/ogi/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/, according to the following timetable: